178 related articles for article (PubMed ID: 38272883)
1. SHMT2 promotes papillary thyroid cancer metastasis through epigenetic activation of AKT signaling.
Sun M; Zhao M; Li R; Zhang Y; Shi X; Ding C; Ma C; Lu J; Yue X
Cell Death Dis; 2024 Jan; 15(1):87. PubMed ID: 38272883
[TBL] [Abstract][Full Text] [Related]
2. miR-215 suppresses papillary thyroid cancer proliferation, migration, and invasion through the AKT/GSK-3β/Snail signaling by targeting ARFGEF1.
Han J; Zhang M; Nie C; Jia J; Wang F; Yu J; Bi W; Liu B; Sheng R; He G; Kong L; Zheng L; Pang R; Ding Z; Chen L; Guan Q; Pan S; Meng X; Xu J; Liu L; Zhang J
Cell Death Dis; 2019 Feb; 10(3):195. PubMed ID: 30814512
[TBL] [Abstract][Full Text] [Related]
3. Induction of serine hydroxymethyltransferase 2 promotes tumorigenesis and metastasis in neuroblastoma.
Clark RA; Qiao J; Jacobson JC; Chung DH
Oncotarget; 2022; 13():32-45. PubMed ID: 35018218
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA‑766 inhibits papillary thyroid cancer progression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway.
Zhao J; Li Z; Chen Y; Zhang S; Guo L; Gao B; Jiang Y; Tian W; Hao S; Zhang X
Int J Oncol; 2019 Jan; 54(1):315-325. PubMed ID: 30387841
[TBL] [Abstract][Full Text] [Related]
5. BGL3 inhibits papillary thyroid carcinoma progression via regulating PTEN stability.
Zhao M; Yang F; Sang C; Yan C; Wang Z
J Endocrinol Invest; 2021 Oct; 44(10):2165-2174. PubMed ID: 33543443
[TBL] [Abstract][Full Text] [Related]
6. Circ_0079558 promotes papillary thyroid cancer progression by binding to miR-26b-5p to activate MET/AKT signaling.
Zheng H; Fu Q; Ma K; Shi S; Fu Y
Endocr J; 2021 Nov; 68(11):1247-1266. PubMed ID: 34565758
[TBL] [Abstract][Full Text] [Related]
7. CRLF1 promotes malignant phenotypes of papillary thyroid carcinoma by activating the MAPK/ERK and PI3K/AKT pathways.
Yu ST; Zhong Q; Chen RH; Han P; Li SB; Zhang H; Yuan L; Xia TL; Zeng MS; Huang XM
Cell Death Dis; 2018 Mar; 9(3):371. PubMed ID: 29515111
[TBL] [Abstract][Full Text] [Related]
8. STAT3-induced upregulation of lncRNA ABHD11-AS1 promotes tumour progression in papillary thyroid carcinoma by regulating miR-1301-3p/STAT3 axis and PI3K/AKT signalling pathway.
Wen J; Wang H; Dong T; Gan P; Fang H; Wu S; Li J; Zhang Y; Du R; Zhu Q
Cell Prolif; 2019 Mar; 52(2):e12569. PubMed ID: 30657221
[TBL] [Abstract][Full Text] [Related]
9. LHPP inhibits cell growth and migration and triggers autophagy in papillary thyroid cancer by regulating the AKT/AMPK/mTOR signaling pathway.
Sun W; Qian K; Guo K; Chen L; Xiang J; Li D; Wu Y; Ji Q; Sun T; Wang Z
Acta Biochim Biophys Sin (Shanghai); 2020 Apr; 52(4):382-389. PubMed ID: 32227107
[TBL] [Abstract][Full Text] [Related]
10. SLC34A2 simultaneously promotes papillary thyroid carcinoma growth and invasion through distinct mechanisms.
He J; Zhou M; Li X; Gu S; Cao Y; Xing T; Chen W; Chu C; Gu F; Zhou J; Jin Y; Ma J; Ma D; Zou Q
Oncogene; 2020 Mar; 39(13):2658-2675. PubMed ID: 32005974
[TBL] [Abstract][Full Text] [Related]
11. LINC00641 impeded the malignant biological behaviors of papillary thyroid carcinoma cells via interacting with IGF2BP1 to reduce GLI1 mRNA stability.
Meng D; Zhao S; Wu L; Ma X; Zhao D; Li Z
Hum Exp Toxicol; 2023; 42():9603271231180856. PubMed ID: 37291850
[TBL] [Abstract][Full Text] [Related]
12. Lysophosphatidic Acid Receptor 5 (LPAR5) Plays a Significance Role in Papillary Thyroid Cancer via Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin (mTOR) Pathway.
Wu CY; Zheng C; Xia EJ; Quan RD; Hu J; Zhang XH; Hao RT
Med Sci Monit; 2020 Jan; 26():e919820. PubMed ID: 31902939
[TBL] [Abstract][Full Text] [Related]
13. A novel lncRNA n384546 promotes thyroid papillary cancer progression and metastasis by acting as a competing endogenous RNA of miR-145-5p to regulate AKT3.
Feng J; Zhou Q; Yi H; Ma S; Li D; Xu Y; Wang J; Yin S
Cell Death Dis; 2019 Jun; 10(6):433. PubMed ID: 31160577
[TBL] [Abstract][Full Text] [Related]
14. PIG3 plays an oncogenic role in papillary thyroid cancer by activating the PI3K/AKT/PTEN pathway.
Xu J; Cai J; Jin X; Yang J; Shen Q; Ding X; Liang Y
Oncol Rep; 2015 Sep; 34(3):1424-30. PubMed ID: 26133772
[TBL] [Abstract][Full Text] [Related]
15. Long non-coding ROR promotes the progression of papillary thyroid carcinoma through regulation of the TESC/ALDH1A1/TUBB3/PTEN axis.
Fan Y; Fan X; Yan H; Liu Z; Wang X; Yuan Q; Xie J; Lu X; Yang Y
Cell Death Dis; 2022 Feb; 13(2):157. PubMed ID: 35173149
[TBL] [Abstract][Full Text] [Related]
16. Long noncoding RNA CASC9 promotes the proliferation and metastasis of papillary thyroid cancer via sponging miR-488-3p.
Chen Y; Li Y; Gao H
Cancer Med; 2020 Mar; 9(5):1830-1841. PubMed ID: 31943867
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-31 inhibits papillary thyroid carcinoma cell biological progression by directly targeting SOX11 and regulating epithelial-to-mesenchymal transition, ERK and Akt signaling pathways.
Wang Y; Liu BG; Zhou CX
Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5863-5873. PubMed ID: 31298337
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of NEAT1 reverses the radioactive iodine resistance of papillary thyroid carcinoma cell via miR-101-3p/FN1/PI3K-AKT signaling pathway.
Liu C; Feng Z; Chen T; Lv J; Liu P; Jia L; Zhu J; Chen F; Yang C; Deng Z
Cell Cycle; 2019 Jan; 18(2):167-203. PubMed ID: 30596336
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of KDM1A suppresses tumour migration and invasion by epigenetically regulating the TIMP1/MMP9 pathway in papillary thyroid cancer.
Zhang W; Sun W; Qin Y; Wu C; He L; Zhang T; Shao L; Zhang H; Zhang P
J Cell Mol Med; 2019 Aug; 23(8):4933-4944. PubMed ID: 31211500
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA TTN-AS1 facilitates tumorigenesis of papillary thyroid cancer through modulating the miR-153-3p/ZNRF2 axis.
Cui Z; Luo Z; Lin Z; Shi L; Hong Y; Yan C
J Gene Med; 2019 May; 21(5):e3083. PubMed ID: 30811764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
